EU Competition Law and Pharmaceuticals (Hardcover)


This timely book discusses the application of the EU competition rules to pharmaceuticals, covering the prohibitions on anticompetitive agreements and abuse of dominance, and merger control. The author team comprises academic experts and private practitioners who analyse recent case law at both EU (and UK) and Member State levels - in the context of current issues and future trends, including those related to COVID-19 - and examine the impact of competition law on the behaviour of the pharmaceutical industry. The book carefully considers the balance between competition and innovation, as well as between competition and regulation. It concludes that competition and regulation are not alternatives, but complementary, and that novel ways of taking into account risk and real innovation through competition assessments have been developed. Integrating an overview of competition law, IP law and pharmaceutical regulation, this book will be an ideal read for scholars and graduate students, as well as private and public practitioners interested in pharmaceutical and European law.

R3,510

Or split into 4x interest-free payments of 25% on orders over R50
Learn more

Discovery Miles35100
Mobicred@R329pm x 12* Mobicred Info
Free Delivery
Delivery AdviceShips in 12 - 17 working days


Toggle WishListAdd to wish list
Review this Item

Product Description

This timely book discusses the application of the EU competition rules to pharmaceuticals, covering the prohibitions on anticompetitive agreements and abuse of dominance, and merger control. The author team comprises academic experts and private practitioners who analyse recent case law at both EU (and UK) and Member State levels - in the context of current issues and future trends, including those related to COVID-19 - and examine the impact of competition law on the behaviour of the pharmaceutical industry. The book carefully considers the balance between competition and innovation, as well as between competition and regulation. It concludes that competition and regulation are not alternatives, but complementary, and that novel ways of taking into account risk and real innovation through competition assessments have been developed. Integrating an overview of competition law, IP law and pharmaceutical regulation, this book will be an ideal read for scholars and graduate students, as well as private and public practitioners interested in pharmaceutical and European law.

Customer Reviews

No reviews or ratings yet - be the first to create one!

Product Details

General

Imprint

Edward Elgar Publishing Ltd

Country of origin

United Kingdom

Series

New Horizons in Competition Law and Economics series

Release date

November 2022

Availability

Expected to ship within 12 - 17 working days

Editors

, ,

Dimensions

234 x 156mm (L x W)

Format

Hardcover

Pages

324

ISBN-13

978-1-80220-440-7

Barcode

9781802204407

Categories

LSN

1-80220-440-7



Trending On Loot